Contamination control is no longer viewed solely through the lens of compliance. Across today's biopharmaceutical manufacturing landscape, it has become a ...
BIO 2026, taking place June 22–25 at the San Diego Convention Center, comes at a pivotal moment for emerging biotech companies. While scienti...
As biotech innovators pursue increasingly complex therapies, the path from discovery to clinical proof of concept is becoming more challenging than ever. F...
NDA submission supported by positive Phase 3 data recently published in JAMA Neurology. Ecopipam is a first-in-class selective dopamine D1 receptor an...
The Novo Nordisk Foundation is funding a new pan-European initiative to accelerate drug discovery and the development of next generation therapeutics for...
The collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in potential option fees and milestone payments for any pr...
Non-dilutive funding will support the commercialization, development, and expansion strategy for Sonire's Ultrasound-Guided HIFU Platform Sonire Therape...
The study achieved the primary endpoint of non-inferiority, with a rate of all-cause mortality (ACM) at Day 42 for olorofim of 23.8% and for AmBisome&r...
Filing acceptance based on data from the phase III SUNMO study where subcutaneous Lunsumio VELO plus Polivy demonstrated a 59% reduction in risk of dis...
Mabion S.A., a Polish biotechnology company, has signed a letter of intent (LoI) with French TechDev company Oddifact SAS to evaluate and advance...
IDBS, a Danaher company and leading provider of cloud software for biopharma, and Alchemi, a leading applied AI company serving the world's largest pharm...
Bayer announced the completion of the acquisition of Perfuse Therapeutics, Inc. As a result, Perfuse Therapeutics will now be fully integrated into Bayer...
Regulatory milestone underscores opportunity for shared regulatory-science and evidence frameworks to support the next generation of therapies. Critical...
Hillhurst Biopharmaceuticals Inc. ("Hillhurst Bio"), a clinical-stage biopharmaceutical company focused on developing novel oral liquid drug products bas...
© 2026 Biopharma Boardroom. All Rights Reserved.
